Apyx Medical Corporation (NASDAQ:APYX) Short Interest Up 22.3% in February

Apyx Medical Corporation (NASDAQ:APYX) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 173,573 shares, a growth of 22.3% from the February 12th total of 141,982 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average trading volume of 64,528 shares, the days-to-cover ratio is currently 2.7 days. Based on an average trading volume of 64,528 shares, the days-to-cover ratio is currently 2.7 days. Currently, 0.5% of the shares of the stock are short sold.

Institutional Trading of Apyx Medical

Several institutional investors and hedge funds have recently made changes to their positions in APYX. Citadel Advisors LLC purchased a new stake in Apyx Medical during the 3rd quarter worth about $28,000. Fisher Asset Management LLC purchased a new position in Apyx Medical in the 2nd quarter valued at about $34,000. Caprock Group LLC acquired a new stake in shares of Apyx Medical during the 3rd quarter worth about $40,000. Osaic Holdings Inc. acquired a new stake in shares of Apyx Medical during the 2nd quarter worth about $50,000. Finally, Franklin Resources Inc. purchased a new stake in shares of Apyx Medical during the third quarter worth about $59,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on APYX. BTIG Research raised Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. Roth Mkm initiated coverage on Apyx Medical in a report on Monday, December 15th. They issued a “buy” rating and a $6.00 target price on the stock. Craig Hallum raised their price target on Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Finally, Wall Street Zen raised Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Apyx Medical presently has an average rating of “Moderate Buy” and an average price target of $6.50.

Apyx Medical Trading Up 0.3%

Shares of APYX opened at $3.63 on Monday. The company has a debt-to-equity ratio of 2.35, a current ratio of 5.00 and a quick ratio of 4.26. Apyx Medical has a 1-year low of $0.76 and a 1-year high of $4.50. The stock has a market cap of $151.84 million, a price-to-earnings ratio of -13.44 and a beta of 1.61. The firm has a 50 day simple moving average of $3.75 and a 200-day simple moving average of $3.34.

Apyx Medical (NASDAQ:APYX) last posted its earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $19.12 million. Apyx Medical had a negative return on equity of 114.95% and a negative net margin of 21.22%. Equities analysts forecast that Apyx Medical will post -0.68 EPS for the current fiscal year.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.